Angiosarcoma (DBCOND0017340)

Identifiers

Synonyms

Angiosarcomas / Angiosarcoma (morphologic abnormality) / Hemangiosarcoma / Hemangiosarcoma (morphologic abnormality) / Haemangiosarcoma NOS / Haemangiosarcoma / Angiosarcoma NOS / Angiosarcoma (disorder) / Haemangioendothelioma malignant / Hemangioendothelioma, malignant (morphologic abnormality) / Hemangioendothelioma malignant

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Sorafenib	A kinase inhibitor used to treat unresectable liver carcinoma, advanced renal carcinoma, and differentiated thyroid carcinoma.	Serine/threonine-protein kinase B-raftarget Receptor-type tyrosine-protein kinase FLT3target RAF proto-oncogene serine/threonine-protein kinasetarget Vascular endothelial growth factor receptor 3target Platelet-derived growth factor receptor betatarget Mast/stem cell growth factor receptor Kittarget Vascular endothelial growth factor receptor 2target Cytochrome P450 3A4enzyme UDP-glucuronosyltransferase 1A9enzyme Cytochrome P450 2B6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Cytochrome P450 2C9enzyme ATP-binding cassette sub-family C member 4transporter ATP-dependent translocase ABCB1transporter ATP-binding cassette sub-family C member 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 1A2enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2D6enzyme UDP-glucuronosyltransferase 1A1enzyme RalA-binding protein 1transporter Fibroblast growth factor receptor 1target Proto-oncogene tyrosine-protein kinase receptor Rettarget Vascular endothelial growth factor receptor 1target Solute carrier organic anion transporter family member 1B1transporter Epidermal growth factor receptortarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06535997	Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT01055028	Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma	Bevacizumab Paclitaxel	treatment	2	terminated
NCT06638931	Agnostic Therapy in Rare Solid Tumors	No drug interventions	treatment	2	recruiting
NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Ipilimumab Nivolumab	treatment	2	active_not_recruiting
NCT05799612	Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma	Filgrastim Interferon alfa Paclitaxel	treatment	1	recruiting
NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	Abemaciclib Anvatabart opadotin Cemiplimab Datopotamab deruxtecan Dostarlimab Doxorubicin Durvalumab Fianlimab Ganetespib Ganitumab Irinotecan Ladiratuzumab vedotin Lasofoxifene Letrozole Menthol Metformin Neratinib Olaparib Paclitaxel Patritumab Pembrolizumab Pertuzumab Pexidartinib SAR-439459 Talazoparib Trastuzumab Trastuzumab duocarmazine Trastuzumab emtansine Trebananib Trilaciclib Tucatinib Veliparib Vepdegestrant Zanidatamab	treatment	2	recruiting
NCT06277154	MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma	Doxorubicin Ifosfamide	treatment	2	not_yet_recruiting
NCT06526897	Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma	No drug interventions	diagnostic	Not Available	not_yet_recruiting
NCT05961761	Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients	Pembrolizumab Propranolol	treatment	2	recruiting
NCT02732678	Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)	Propranolol	treatment	1 / 2	unknown_status
NCT02584309	Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma	Dexrazoxane Doxorubicin	treatment	2	completed
NCT04607200	AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma	Balstilimab Zalifrelimab	treatment	2	withdrawn
NCT04518124	Propranolol in Angiosarcoma	Propranolol	treatment	2	completed
NCT04055220	Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas	Regorafenib	treatment	Not Available	recruiting
NCT01303497	Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas	Bevacizumab Paclitaxel	treatment	2	completed
NCT00887809	Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes	Bevacizumab Docetaxel Gemcitabine	treatment	2	completed
NCT02212015	Evaluation of Votrient in Angiosarcoma	Paclitaxel Pazopanib	treatment	2	terminated
NCT05116800	Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma	Docetaxel Elraglusib Gemcitabine	treatment	2	withdrawn
NCT06375941	Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars	No drug interventions	Not Available	Not Available	recruiting
NCT05859074	A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer	Pembrolizumab	treatment	1	active_not_recruiting
NCT04906876	A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Docetaxel Elraglusib Gemcitabine	treatment	2	withdrawn
NCT02625389	Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.	Ethiodized oil	treatment	4	unknown_status
NCT04293289	Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma	No drug interventions	treatment	Not Available	completed
NCT01786889	Identification, Molecular Epidemiology Angiosarcoma of the Liver France	No drug interventions	prevention	Not Available	unknown_status
NCT03860272	Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer	Balstilimab Botensilimab	treatment	1	recruiting
NCT03331250	Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)	Eribulin	treatment	2	active_not_recruiting